Dear Friend;
Attached is a news release announcing the Company’s recent exhibition in Milan, Italy at EuroEcho. Here is some background:
1. EuroEcho is one of the two major medical conferences each year which focus solely on echocardiography. This year 4,200 medical experts attend the event.
2. Ventripoint had an exhibit booth where we featured live scanning along with the reconstruction process to measure volumes and ejection fractions for all 4 chambers of the heart using our new VMS3.0 machine (see attached picture).
3. The response was excellent with over 80 cardiologists viewing the demonstrations and indicating they wanted to be sent additional information. Our sales team is doing that now and we expect to be able to start filling orders for the VMS3.0 in February once we receive safety certificates and regulatory approvals.
4. It was especially nice to have Dr. Kutty, who has been along-time supporter of the Company present a new paper showing the VMS was accurate and easy to use for 3D scans for the right ventricle (RV) and left ventricle (LV) in normals and patients with congenital heart disease. This is the first data on LV published and it was well received but the attendees at EuroEcho. Dr. Kutty is a leader in the field of paediatric cardiology and is now at Duke University.
5. Having paper at the conference always increases interest and we continue the effort to make people aware of the VMS and its advanced capabilities. People were especially pleased to see the new tracking system which allows for patient repositioning during the image acquisition process. This was a persistent irritation with the VMS+ which while some sonographers were able to make it work, others struggled.
6. The manufacturing cost of the VMS3.0 is a fraction of the VMS+, so this will improve margins and also allow us to offer a leasing option to customers who do not have the capital budget to acquire the VMS.
7. We also took the opportunity at the show to meet with most the other ultrasound companies (GE, Siemens, Phillips, Hitachi, Whale, etc.) to show them the VMS3.0 and discuss how we could work together in the future. We identified a number of opportunities and will be following up with the potential partners over the next few months.
Thank you for your continue interest and as usual if you have questions, please contact me.
Regards,
George Adams, PhD, ICD.D
CEO
Ventripoint Diagnostics Ltd..
Cell: 519-803-6937
TSXV: VPT